SUTRO BIOPHARMA, INC. Proceeds from Common Stock Issued
SUTRO BIOPHARMA, INC. (STRO) reported Proceeds from Common Stock Issued of $102.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $0.00.
- SUTRO BIOPHARMA, INC. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $0.00.
- SUTRO BIOPHARMA, INC. proceeds from issuance of common stock for the quarter ending 2024-12-31 was $0.00.
- SUTRO BIOPHARMA, INC. proceeds from issuance of common stock for the quarter ending 2024-09-30 was $0.00.
- SUTRO BIOPHARMA, INC. proceeds from issuance of common stock for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. proceeds from issuance of common stock for fiscal 2024 was $25.00M.
- SUTRO BIOPHARMA, INC. proceeds from issuance of common stock for fiscal 2023 was $0.00.
- SUTRO BIOPHARMA, INC. proceeds from issuance of common stock for fiscal 2022 was $0.00.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $102.66M 10-Q · filed 2026-08-12 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 10-K · filed 2026-03-23 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-12 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $25.00M 10-K · filed 2026-03-23 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $25.00M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $25.00M 10-Q · filed 2025-08-07 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-13 | $11.97M 10-K · filed 2024-03-25 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-13 | $56.27M 10-K · filed 2023-03-30 | |||
| 2020-12-31 | $143.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $251.41M 10-K · filed 2023-03-30 | |||
| 2020-09-30 | $108.25M 10-Q · filed 2020-11-05 | ||||
| 2019-12-31 | -$327.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |